Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice

European Journal of Pharmacology

Volumn 645, Issue 1-3, 2010, Pages 185-191

  Tanaka, Hirotsugu ^a   Nagashima, Takeyuki ^a   Shimaya, Akiyoshi ^a   Urano, Yasuharu ^a   Shimokawa, Teruhiko ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Db db mouse; Foxo1; Gluconeogenesis; Hypertriglyceridemia; Type 2 diabetes mellitus

Indexed keywords

2 CYCLOPENTYL N [2,4 DICHLORO 3 [(ISOQUINOLIN 5 YLOXY)METHYL]PHENYL] N METHYLACETAMIDE; APOLIPOPROTEIN C3; AS 1708727; GLUCOSE; GLUCOSE 6 PHOSPHATASE; ORAL ANTIDIABETIC AGENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ACETANILIDES; ANIMALS; APOLIPOPROTEIN C-III; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; FORKHEAD TRANSCRIPTION FACTORS; GLUCONEOGENESIS; GLUCOSE-6-PHOSPHATASE; HEPATOCYTES; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; ISOQUINOLINES; MALE; MICE; MICE, INBRED C57BL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); TRIGLYCERIDES;

EID: 77956188526     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.018     Document Type: Article

References (31)

1. Ai M., Otokozawa S., Schaefer E.J., Asztalos B.F., Nakajima K., Shrader P., Kathiresan S., Meigs J.B., Williams G., Nathan D.M. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clinica chimica acta; international journal of clinical chemistry 2009, 406:71-74.
2. Altomonte J., Richter A., Harbaran S., Suriawinata J., Nakae J., Thung S.N., Meseck M., Accili D., Dong H. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. The American Journal of Physiology 2003, 285:E718-E728.
3. Altomonte J., Cong L., Harbaran S., Richter A., Xu J., Meseck M., Dong H.H. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. The Journal of Clinical Investigation 2004, 114:1493-1503.
4. Boden G., Chen X., Stein T.P. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. The American Journal of Physiology 2001, 280:E23-E30.
5. Chaput E., Saladin R., Silvestre M., Edgar A.D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochemical and Biophysical Research Communications 2000, 271:445-450.
6. Chen X., Matthews J., Zhou L., Pelton P., Liang Y., Xu J., Yang M., Cryan E., Rybczynski P., Demarest K. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism, Clinical and Experimental 2008, 57:1516-1525.
7. Chitturi S., Abeygunasekera S., Farrell G.C., Holmes-Walker J., Hui J.M., Fung C., Karim R., Lin R., Samarasinghe D., Liddle C., Weltman M., George J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379. Baltimore, Md.
8. Hall R.K., Yamasaki T., Kucera T., Waltner-Law M., O'Brien R., Granner D.K. Regulation of phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein-1 gene expression by insulin. The role of winged helix/forkhead proteins. The Journal of Biological Chemistry 2000, 275:30169-30175.
9. Kalmar T., Seres I., Balogh Z., Kaplar M., Winkler G., Paragh G. Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes & Metabolism 2005, 31:574-580.
10. Kawakami A., Osaka M., Tani M., Azuma H., Sacks F.M., Shimokado K., Yoshida M. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008, 118:731-742.
11. Li W.W., Dammerman M.M., Smith J.D., Metzger S., Breslow J.L., Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. The Journal of Clinical Investigation 1995, 96:2601-2605.
12. Maeda N., Li H., Lee D., Oliver P., Quarfordt S.H., Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. The Journal of Biological Chemistry 1994, 269:23610-23616.
13. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
14. Matsumoto M., Pocai A., Rossetti L., Depinho R.A., Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metabolism 2007, 6:208-216.
15. Matsuzaki H., Daitoku H., Hatta M., Aoyama H., Yoshimochi K., Fukamizu A. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:11278-11283.
16. Nakae J., Barr V., Accili D. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. The EMBO Journal 2000, 19:989-996.
17. Nakae J., Kitamura T., Silver D.L., Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. The Journal of Clinical Investigation 2001, 108:1359-1367.
18. Nakae J., Biggs W.H., Kitamura T., Cavenee W.K., Wright C.V., Arden K.C., Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nature Genetics 2002, 32:245-253.
19. Onuma H., Vander Kooi B.T., Boustead J.N., Oeser J.K., O'Brien R.M. Correlation between FOXO1a (FKHR) and FOXO3a (FKHRL1) binding and the inhibition of basal glucose-6-phosphatase catalytic subunit gene transcription by insulin. Molecular Endocrinology 2006, 20:2831-2847. Baltimore, Md.
20. Perriello G., Pampanelli S., Del Sindaco P., Lalli C., Ciofetta M., Volpi E., Santeusanio F., Brunetti P., Bolli G.B. Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Diabetes 1997, 46:1010-1016.
21. Perrot V., Rechler M.M. The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Molecular Endocrinology 2005, 19:2283-2298. Baltimore, Md.
22. Pollin T.I., Damcott C.M., Shen H., Ott S.H., Shelton J., Horenstein R.B., Post W., McLenithan J.C., Bielak L.F., Peyser P.A., Mitchell B.D., Miller M., O'Connell J.R., Shuldiner A.R. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705. New York, N.Y.
23. Qu S., Altomonte J., Perdomo G., He J., Fan Y., Kamagate A., Meseck M., Dong H.H. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology 2006, 147:5641-5652.
24. Samuel V.T., Choi C.S., Phillips T.G., Romanelli A.J., Geisler J.G., Bhanot S., McKay R., Monia B., Shutter J.R., Lindberg R.A., Shulman G.I., Veniant M.M. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 2006, 55:2042-2050.
25. Scott D.K., O'Doherty R.M., Stafford J.M., Newgard C.B., Granner D.K. The repression of hormone-activated PEPCK gene expression by glucose is insulin-independent but requires glucose metabolism. The Journal of Biological Chemistry 1998, 273:24145-24151.
26. Streeper R.S., Svitek C.A., Chapman S., Greenbaum L.E., Taub R., O'Brien R.M. A multicomponent insulin response sequence mediates a strong repression of mouse glucose-6-phosphatase gene transcription by insulin. The Journal of Biological Chemistry 1997, 272:11698-11701.
27. Stumvoll M., Meyer C., Perriello G., Kreider M., Welle S., Gerich J. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. The American Journal of Physiology 1998, 274:E817-E826.
28. Tang E.D., Nunez G., Barr F.G., Guan K.L. Negative regulation of the forkhead transcription factor FKHR by Akt. The Journal of Biological Chemistry 1999, 274:16741-16746.
29. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
30. Valenti L., Rametta R., Dongiovanni P., Maggioni M., Fracanzani A.L., Zappa M., Lattuada E., Roviaro G., Fargion S. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008, 57:1355-1362.
31. Wajngot A., Chandramouli V., Schumann W.C., Ekberg K., Jones P.K., Efendic S., Landau B.R. Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism, Clinical and Experimental 2001, 50:47-52.